4.7 Article

Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Clinical Neurology

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Oskar Hansson et al.

Summary: Blood-based markers have the potential to revolutionize the diagnosis and prognosis of Alzheimer's disease and improve the design of clinical trials. However, further research is needed before widespread use.

ALZHEIMERS & DEMENTIA (2022)

Article Clinical Neurology

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

Joel Simren et al.

Summary: P-tau181 shows potential as an effective diagnostic and prognostic biomarker in AD, detecting the disease at MCI and dementia stages and being strongly associated with cognitive decline and gray matter loss.

ALZHEIMERS & DEMENTIA (2021)

Article Clinical Neurology

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andrea L. Benedet et al.

Summary: The study suggests that plasma GFAP is a sensitive biomarker for detecting reactive astrogliosis and Aβ pathology in early stages of AD, outperforming CSF GFAP. Plasma GFAP levels accurately discriminate between Aβ-positive and Aβ-negative individuals, with higher accuracy than CSF GFAP.

JAMA NEUROLOGY (2021)

Article Clinical Neurology

Development and validation of a high-sensitivity assay for measuring p217+tau in plasma

Gallen Triana-Baltzer et al.

Summary: The plasma p217+tau assay showed high accuracy and sensitivity in diagnosing AD, making it a promising peripheral biomarker for A or T status.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2021)

Article Clinical Neurology

Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70

Ashvini Keshavan et al.

Summary: The study compared three different blood-based techniques for identifying early stage Alzheimer's disease, with mass spectrometry plasma measures performing significantly better than other measures.
Article Clinical Neurology

Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70

Ashvini Keshavan et al.

Summary: The study compared three different blood-based techniques to detect amyloid PET positivity in dementia-free individuals, finding that mass spectrometry plasma measures performed significantly better than other measures, with higher sensitivity and specificity for detecting amyloid PET positivity.
Article Medicine, General & Internal

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Sebastian Palmqvist et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Immunology

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Nicolas R. Barthelemy et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Editorial Material Neurosciences

Blood Biomarkers: Democratizing Alzheimer's Diagnostics

Henrik Zetterberg et al.

NEURON (2020)

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

Article Multidisciplinary Sciences

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Akinori Nakamura et al.

NATURE (2018)

Article Clinical Neurology

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes

Inge M. W. Verberk et al.

ANNALS OF NEUROLOGY (2018)

Article Multidisciplinary Sciences

Plasma β-amyloid in Alzheimer's disease and vascular disease

Shorena Janelidze et al.

SCIENTIFIC REPORTS (2016)